Paul Matteis
Stock Analyst at Stifel
(3.20)
# 1,074
Out of 5,237 analysts
131
Total ratings
48.28%
Success rate
2.02%
Average return
Main Sectors:
Stocks Rated by Paul Matteis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DFTX Definium Therapeutics | Initiates: Buy | $30 | $21.40 | +40.19% | 1 | Apr 17, 2026 | |
| IMUX Immunic | Initiates: Buy | $25 | $12.00 | +108.33% | 1 | Apr 17, 2026 | |
| LBRX LB Pharmaceuticals | Maintains: Buy | $35 → $40 | $32.70 | +22.34% | 3 | Mar 27, 2026 | |
| KALV KalVista Pharmaceuticals | Maintains: Buy | $39 → $42 | $26.71 | +57.24% | 2 | Mar 26, 2026 | |
| IONS Ionis Pharmaceuticals | Maintains: Hold | $73 → $77 | $75.38 | +2.15% | 7 | Feb 26, 2026 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Hold | $25 → $24 | $21.80 | +10.09% | 7 | Feb 26, 2026 | |
| VRTX Vertex Pharmaceuticals | Maintains: Hold | $445 → $466 | $435.17 | +7.08% | 21 | Feb 13, 2026 | |
| QURE uniQure | Maintains: Buy | $50 → $40 | $27.64 | +44.72% | 3 | Dec 11, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $183 → $188 | $150.59 | +24.84% | 11 | Dec 11, 2025 | |
| DYN Dyne Therapeutics | Maintains: Buy | $36 → $39 | $18.46 | +111.27% | 5 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $495 → $508 | $284.84 | +78.35% | 16 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $30.09 | -6.95% | 1 | Nov 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $2 → $3 | $1.87 | +60.43% | 3 | Nov 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $73 → $61 | $52.58 | +16.01% | 11 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $144 → $202 | $197.95 | +2.05% | 7 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $12 | $1.70 | +605.88% | 3 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $78 → $94 | $87.39 | +7.56% | 2 | May 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $32 | $45.95 | -30.36% | 1 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $32 | $21.26 | +50.52% | 2 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $11 | $9.65 | +13.99% | 1 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $4 | $2.05 | +95.12% | 4 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $10 | $24.53 | -59.23% | 3 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $44 → $60 | $30.85 | +94.52% | 2 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $25 → $36 | $35.47 | +1.49% | 8 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $38.43 | -8.93% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $29 | $13.65 | +112.45% | 1 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $6.12 | +226.80% | 1 | Nov 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $0.67 | +1,681.47% | 1 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $2.57 | +950.58% | 1 | Jul 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $53 → $64 | $7.07 | +805.23% | 1 | Feb 21, 2018 |
Definium Therapeutics
Apr 17, 2026
Initiates: Buy
Price Target: $30
Current: $21.40
Upside: +40.19%
Immunic
Apr 17, 2026
Initiates: Buy
Price Target: $25
Current: $12.00
Upside: +108.33%
LB Pharmaceuticals
Mar 27, 2026
Maintains: Buy
Price Target: $35 → $40
Current: $32.70
Upside: +22.34%
KalVista Pharmaceuticals
Mar 26, 2026
Maintains: Buy
Price Target: $39 → $42
Current: $26.71
Upside: +57.24%
Ionis Pharmaceuticals
Feb 26, 2026
Maintains: Hold
Price Target: $73 → $77
Current: $75.38
Upside: +2.15%
ACADIA Pharmaceuticals
Feb 26, 2026
Maintains: Hold
Price Target: $25 → $24
Current: $21.80
Upside: +10.09%
Vertex Pharmaceuticals
Feb 13, 2026
Maintains: Hold
Price Target: $445 → $466
Current: $435.17
Upside: +7.08%
uniQure
Dec 11, 2025
Maintains: Buy
Price Target: $50 → $40
Current: $27.64
Upside: +44.72%
Neurocrine Biosciences
Dec 11, 2025
Maintains: Buy
Price Target: $183 → $188
Current: $150.59
Upside: +24.84%
Dyne Therapeutics
Dec 11, 2025
Maintains: Buy
Price Target: $36 → $39
Current: $18.46
Upside: +111.27%
Dec 11, 2025
Maintains: Buy
Price Target: $495 → $508
Current: $284.84
Upside: +78.35%
Nov 21, 2025
Initiates: Buy
Price Target: $28
Current: $30.09
Upside: -6.95%
Nov 17, 2025
Maintains: Hold
Price Target: $2 → $3
Current: $1.87
Upside: +60.43%
Nov 6, 2025
Downgrades: Hold
Price Target: $73 → $61
Current: $52.58
Upside: +16.01%
Nov 6, 2025
Upgrades: Buy
Price Target: $144 → $202
Current: $197.95
Upside: +2.05%
Sep 25, 2025
Maintains: Buy
Price Target: $9 → $12
Current: $1.70
Upside: +605.88%
May 29, 2025
Maintains: Buy
Price Target: $78 → $94
Current: $87.39
Upside: +7.56%
Mar 4, 2025
Initiates: Buy
Price Target: $32
Current: $45.95
Upside: -30.36%
Feb 27, 2025
Maintains: Buy
Price Target: $18 → $32
Current: $21.26
Upside: +50.52%
Feb 27, 2025
Initiates: Buy
Price Target: $11
Current: $9.65
Upside: +13.99%
Dec 16, 2024
Downgrades: Hold
Price Target: $4
Current: $2.05
Upside: +95.12%
Nov 13, 2024
Maintains: Buy
Price Target: $32 → $10
Current: $24.53
Upside: -59.23%
Nov 12, 2024
Maintains: Buy
Price Target: $44 → $60
Current: $30.85
Upside: +94.52%
Nov 5, 2024
Upgrades: Buy
Price Target: $25 → $36
Current: $35.47
Upside: +1.49%
Jul 2, 2024
Initiates: Buy
Price Target: $35
Current: $38.43
Upside: -8.93%
Apr 30, 2024
Initiates: Buy
Price Target: $29
Current: $13.65
Upside: +112.45%
Nov 28, 2023
Initiates: Buy
Price Target: $20
Current: $6.12
Upside: +226.80%
Nov 14, 2023
Initiates: Buy
Price Target: $12
Current: $0.67
Upside: +1,681.47%
Jul 26, 2021
Initiates: Buy
Price Target: $27
Current: $2.57
Upside: +950.58%
Feb 21, 2018
Maintains: Outperform
Price Target: $53 → $64
Current: $7.07
Upside: +805.23%